Article (Scientific journals)
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Miller, Paul D; Epstein, Sol; Sedarati, Farhad et al.
2008In Current Medical Research and Opinion, 24 (1), p. 207-13
Peer Reviewed verified by ORBi
 

Files


Full Text
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis results from the head-to-head MOTION study_CMRO 2007_Miller et al.pdf
Publisher postprint (286.24 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
Administration, Oral; Aged; Aged, 80 and over; Alendronate/administration & dosage/adverse effects; Algorithms; Bone Density/drug effects; Bone Density Conservation Agents/administration & dosage; Diphosphonates/administration & dosage/adverse effects; Double-Blind Method; Drug Administration Schedule; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal/drug therapy; Treatment Outcome
Abstract :
[en] OBJECTIVE: Oral ibandronate 150 mg is the first bisphosphonate approved for once-monthly treatment of postmenopausal osteoporosis. To investigate whether once-monthly ibandronate 150 mg increases lumbar spine and total hip bone mineral density (BMD) to the same degree as weekly alendronate 70 mg. RESEARCH DESIGN AND METHODS: This was a 12-month, randomised, multinational, multicentre, double-blind, double-dummy, parallel-group, non-inferiority trial, conducted in 65 centres in North America, Latin America, Europe and South Africa. The study included postmenopausal women, mean lumbar spine (L2-L4) BMD T-score < -2.5 and > or = -5.0. Patients received either ibandronate 150 mg once monthly or alendronate 70 mg once weekly. MAIN OUTCOME MEASURES: Co-primary efficacy endpoints were 12-month change (%) from baseline in mean lumbar spine and total hip BMD. Changes (%) from baseline in trochanter and femoral neck BMD were also evaluated. Adverse events were monitored throughout. Once-monthly ibandronate was considered non-inferior to weekly alendronate if the lower boundary of the one-sided 97.5% confidence interval (CI) (or two-sided 95% CI) was > or = -1.41% for lumbar spine and > or = -0.87% for total hip. RESULTS: Mean relative 12-month changes were 5.1% and 5.8% (95% CI for difference, -1.13, -0.23) in lumbar spine and 2.9% and 3.0% (95% CI for difference, -0.38, 0.18) in total hip BMD with once-monthly ibandronate and weekly alendronate, respectively; meeting the non-inferiority criteria at both sites. Gains in trochanter and femoral neck BMD were similar with both treatments. Both regimens were well tolerated. TRIAL REGISTRATION: The MOTION study is registered with the International Federation of Pharmaceutical Manufacturers and Associations trial portal, under the ID number MM17385. CONCLUSIONS: Once-monthly ibandronate was shown to be clinically comparable to weekly alendronate at increasing BMD after 12 months in both the lumbar spine and total hip.
Disciplines :
General & internal medicine
Author, co-author :
Miller, Paul D
Epstein, Sol
Sedarati, Farhad
Reginster, Jean-Yves  ;  Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique
Language :
English
Title :
Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study.
Publication date :
2008
Journal title :
Current Medical Research and Opinion
ISSN :
0300-7995
eISSN :
1473-4877
Publisher :
LibraPharm Ltd, Newbury Berkshire, United Kingdom
Volume :
24
Issue :
1
Pages :
207-13
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 02 September 2009

Statistics


Number of views
94 (2 by ULiège)
Number of downloads
1 (0 by ULiège)

Scopus citations®
 
72
Scopus citations®
without self-citations
57
OpenCitations
 
52

Bibliography


Similar publications



Contact ORBi